COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients

References

• Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192. doi:10.1038/s41579-018-0118-930531947
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Y. Animal coronaviruses: a brief introduction In: Wang L. (eds) Animal Coronaviruses. Springer Protocols Handbooks. Humana Press, New York, NY. doi:10.1007/978-1-4939-3414-0_1
   Google Scholar
• Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33(4):869–889. doi:10.1016/j.idc.2019.07.00131668196
   PubMed Web of Science ®Google Scholar
• Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018;22(15):4956–4961. doi:10.26355/eurrev_201808_1563530070331
   PubMed Web of Science ®Google Scholar
• Yu P, Zhu J, Zhang Z, Han Y. A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J Infect Dis. 2020;221(11):1757–1761. doi:10.1093/infdis/jiaa07732067043
   PubMed Web of Science ®Google Scholar
• Kotfis K, Skonieczna-Zydecka K. COVID-19: gastrointestinal symptoms and potential sources of 2019-nCoV transmission. Anaesthesiol Intensive Ther. 2020. doi:10.5114/ait.2020.93867
   Web of Science ®Google Scholar
• Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology. 2020;158(6):1518–1519. doi:10.1053/j.gastro.2020.02.05432142785
   PubMed Web of Science ®Google Scholar
• WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Interim guidance. 2020 Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 313, 2020.
   Google Scholar
• Kotfis K, Williams Roberson S, Wilson J, Pun BT, Ely EW. COVID-19: what do we need to know about ICU delirium during the SARS-CoV-2 pandemic? Anaesthesiol Intensive Ther. 2020;52(2):132–138. doi:10.5114/ait.2020.95164
   PubMed Web of Science ®Google Scholar
• Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020;24(1):176. doi:10.1186/s13054-020-02882-x32345343
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Kukla M, Skonieczna-Żydecka K, Kotfis K, et al. COVID-19, MERS and SARS with concomitant liver injury—systematic review of the existing literature. J Clin Med. 2020;9(5):5. doi:10.3390/jcm9051420
   Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239. doi:10.1001/jama.2020.2648
   PubMed Web of Science ®Google Scholar
• Conthe P, Márquez Contreras E, Aliaga Pérez A, et al. Treatment compliance in chronic illness: current situation and future perspectives. Rev Clin Esp. 2014;214(6):336–344. doi:10.1016/j.rce.2014.03.00824816042
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610. doi:10.1161/CIRCULATIONAHA.104.51046115897343
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-332171076
   PubMed Web of Science ®Google Scholar
• Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus. 2020;12(3):e7355. doi:10.7759/cureus.735532328367
   PubMed Web of Science ®Google Scholar
• Xu G, Yang Y, Du Y, et al. Clinical pathway for early diagnosis of COVID-19: updates from experience to evidence-based practice. Clin Rev Allergy Immunol. 2020. doi:10.1007/s12016-020-08792-8
   Web of Science ®Google Scholar
• Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–237. doi:10.1038/s41581-019-0244-232024986
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2018;36(12):2284–2309. doi:10.1097/HJH.000000000000196130379783
   PubMed Web of Science ®Google Scholar
• Hamming I, Cooper ME, Haagmans BL, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007;212(1):1–11. doi:10.1002/path.216217464936
   PubMed Web of Science ®Google Scholar
• Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280(34):30113–30119. doi:10.1074/jbc.M50511120015983030
   PubMed Web of Science ®Google Scholar
• Palau V, Riera M, Soler MJ. ADAM17 inhibition may exert a protective effect on COVID-19. Nephrol Dial Transplant. 2020;35(6):1071–1072. doi:10.1093/ndt/gfaa09332291449
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.05232142651
   PubMed Web of Science ®Google Scholar
• Zores F, Rebeaud ME. COVID and the renin-angiotensin system: are hypertension or its treatments deleterious? Front Cardiovasc Med. 2020;7:71.32391384
   PubMed Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi:10.1007/s00134-020-05985-932125455
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. 2020.
   Google Scholar
• Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020;2020.03.14.988345. doi:10.1101/2020.03.14.988345
   Google Scholar
• Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1–9. doi:10.1161/01.res.87.5.e110969042
   PubMed Web of Science ®Google Scholar
• Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond). 2020;134(5):543–545. doi:10.1042/CS2020016332167153
   PubMed Web of Science ®Google Scholar
• Turner AJ. ACE2 Cell Biology, Regulation, and Physiological Functions. The Protective Arm of the Renin Angiotensin System (RAS). 2015;185–189. doi:10.1016/B978-0-12-801364-9.00025-0
   Google Scholar
• Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi:10.1002/path.157015141377
   PubMed Web of Science ®Google Scholar
• Magrone T, Magrone M, Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target – a perspective. Endocr Metab Immune Disord Drug Targets. 2020;20. doi:10.2174/1871530320666200427112902
   Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi:10.1038/nature0214514647384
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–1966. doi:10.1056/NEJMoa03078112690092
   PubMed Web of Science ®Google Scholar
• Lei C, Fu W, Qian K, et al. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. bioRxiv. 2020. doi:10.1101/2020.02.01.929976
   Google Scholar
• Zhang Q, Cong M, Wang N, et al. Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: a case-control study. Medicine. 2018;97(42):e12917. doi:10.1097/MD.000000000001291730335025
   PubMed Web of Science ®Google Scholar
• Chen YY, Zhang P, Zhou XM, et al. Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites. J Clin Pharm Ther. 2018;43(2):189–195. doi:10.1111/jcpt.1262528895159
   PubMed Web of Science ®Google Scholar
• Burrell LM, Harrap SB, Velkoska E, Patel SK. The ACE2 gene: its potential as a functional candidate for cardiovascular disease. Clin Sci (Lond). 2013;124(2):65–76. doi:10.1042/CS2012026923013041
   PubMed Web of Science ®Google Scholar
• He J, Lu Y-P, Li J, et al. Fetal but not maternal Angiotensin Converting Enzyme (ACE)-2 gene Rs2074192 polymorphism is associated with increased risk of being a Small For Gestational Age (SGA) newborn. Kidney Blood Press Res. 2018;43(5):1596–1606. doi:10.1159/00049444930347406
   PubMed Web of Science ®Google Scholar
• Pan Y, Wang T, Li Y, et al. Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China. Lipids Health Dis. 2018;17(1):241. doi:10.1186/s12944-018-0890-630342552
   PubMed Web of Science ®Google Scholar
• Lu N, Yang Y, Wang Y, et al. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Mol Biol Rep. 2012;39(6):6581–6589. doi:10.1007/s11033-012-1487-122297693
   PubMed Web of Science ®Google Scholar
• Fan X, Wang Y, Sun K, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of captopril in women. Clin Pharmacol Ther. 2007;82(2):187–196. doi:10.1038/sj.clpt.610021417473847
   PubMed Web of Science ®Google Scholar
• Chen YY, Liu D, Zhang P, et al. Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors. J Hum Hypertens. 2016;30(12):766–771. doi:10.1038/jhh.2016.2427121444
   PubMed Web of Science ®Google Scholar
• Vangjeli C, Dicker P, Tregouet D-A, Shields DC, Evans A, Stanton AV. A polymorphism in ACE2 is associated with a lower risk for fatal cardiovascular events in females: the MORGAM project. J Renin Angiotensin Aldosterone Syst. 2011;12(4):504–509. doi:10.1177/147032031140555721490025
   PubMed Web of Science ®Google Scholar
• Malard L, Kakinami L, O’Loughlin J, et al. The association between the angiotensin-converting enzyme-2 gene and blood pressure in a cohort study of adolescents. BMC Med Genet. 2013;14:117. doi:10.1186/1471-2350-14-11724191856
   PubMed Web of Science ®Google Scholar
• Fan Z, Wu G, Yue M, et al. Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism. Life Sci. 2019;225:39–45. doi:10.1016/j.lfs.2019.03.05930917908
   PubMed Web of Science ®Google Scholar
• Lieb W, Graf J, Gotz A, et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA augsburg echocardiographic substudy. J Mol Med (Berl). 2006;84(1):88–96. doi:10.1007/s00109-005-0718-516283142
   PubMed Web of Science ®Google Scholar
• Wang S-X, Tao T, Fu Z-Q, Xie X-Z, Wang H, Wang Y-T. Polymorphisms of angiotensin-converting enzyme 2 gene confer a risk to lone atrial fibrillation in Chinese male patients. Chin Med J (Engl). 2013;126(24):4608–4611.24342297
   PubMed Web of Science ®Google Scholar
• Wu X, Zhu B, Zou S, Shi J. The association between ACE2 gene polymorphism and the stroke recurrence in Chinese population. J Stroke Cerebrovasc Dis. 2018;27(10):2770–2780. doi:10.1016/j.jstrokecerebrovasdis.2018.06.00130056001
   PubMed Web of Science ®Google Scholar
• Liu D, Chen Y, Zhang P, et al. Association between circulating levels of ACE2-Ang-(1-7)-MAS axis and ACE2 gene polymorphisms in hypertensive patients. Medicine. 2016;95(24):e3876. doi:10.1097/MD.000000000000387627310975
   PubMed Web of Science ®Google Scholar
• Adamzik M, Frey U, Sixt S, et al. ACE I/D but not AGT (−6)A/G polymorphism is a risk factor for mortality in ARDS. Eur Respir J. 2007;29(3):482–488. doi:10.1183/09031936.0004610617107992
   PubMed Web of Science ®Google Scholar
• Saab YB, Gard PR, Overall ADJ. The geographic distribution of the ACE II genotype: a novel finding. Genet Res. 2007;89(4):259–267. doi:10.1017/S001667230700901918208631
   PubMed Web of Science ®Google Scholar
• Chiu RWK, Tang NLS, Hui DSC, et al. ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. Clin Chem. 2004;50(9):1683–1686. doi:10.1373/clinchem.2004.03543615331509
   PubMed Web of Science ®Google Scholar
• Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004;2(1):19. doi:10.1186/1741-7015-2-1915151696
   PubMed Web of Science ®Google Scholar
• Delanghe JR, Speeckaert MM, De Buyzere ML. The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta. 2020;505:192–193. doi:10.1016/j.cca.2020.03.03132220422
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 2010;74(3):405–410. doi:10.1253/circj.cj-10-004520134095
   PubMed Web of Science ®Google Scholar
• Stawiski EW, Diwanji D, Suryamohan K, et al. Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility. bioRxiv. 2020;2020.04.07.024752. doi:10.1101/2020.04.07.024752
   Google Scholar
• Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020;6(1):4–7. doi:10.1038/s41421-020-0147-132025334
   PubMed Web of Science ®Google Scholar
• Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26(4):506–510. doi:10.1038/s41591-020-0822-732284616
   PubMed Web of Science ®Google Scholar
• Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838–14843. doi:10.1074/jbc.M20058120011815627
   PubMed Web of Science ®Google Scholar
• Serfozo P, Wysocki J, Gulua G, et al. Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (Angiotensin-Converting Enzyme 2)-independent. Hypertens. 2020;75(1):173–182. doi:10.1161/HYPERTENSIONAHA.119.14071
   PubMed Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-832171062
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020. doi:10.1161/CIRCRESAHA.120.317134
   Web of Science ®Google Scholar
• Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017;125(Pt A):21–38. doi:10.1016/j.phrs.2017.06.00528619367
   PubMed Web of Science ®Google Scholar
• Caldeira D, Alarcao J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345(jul11 1):e4260. doi:10.1136/bmj.e426022786934
   PubMed Web of Science ®Google Scholar
• Wirtz H, Hasenclever D, Schwabe K, et al. ACE inhibitor for lung protection during mechanical ventilation for acute lung injury – results of the double-blind, placebo controlled, randomised ACEmeVENT pilot study. In: B16. Critical Care: New Insights From Clinical Trials. American Thoracic Society International Conference Abstracts American Thoracic Society; 2017:A2895–A2895. doi:10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A2895
   Google Scholar
• Kim J, Choi SM, Lee J, et al. Effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: a retrospective case control study. Korean J Crit Care Med. 2017;32(2):154–163. doi:10.4266/kjccm.2016.0097631723629
   PubMedGoogle Scholar
• Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E014. doi:10.3760/cma.j.issn.1001-0939.2020.001432061198
   PubMedGoogle Scholar
• Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E004. doi:10.3760/cma.j.cn112148-20200220-0010532120458
   PubMedGoogle Scholar
• Danser AHJ, Batenburg WW, van den Meiracker AH, Danilov SM. ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? Pharmacol Ther. 2007;113(3):607–618. doi:10.1016/j.pharmthera.2006.12.00117257685
   PubMed Web of Science ®Google Scholar
• Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc. 2020;9(7):e016509. doi:10.1161/JAHA.120.01650932233753
   PubMed Web of Science ®Google Scholar
• Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020;92(6):595–601. doi:10.1002/jmv.2572632100877
   PubMed Web of Science ®Google Scholar
• Mancia G, Rea F, Ph D, et al. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020:1–10. doi:10.1056/NEJMoa2006923
   Web of Science ®Google Scholar
• Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;1–8. doi:10.1056/NEJMoa2007621
   Web of Science ®Google Scholar
• Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020:1–8. doi:10.1056/NEJMoa2008975
   Web of Science ®Google Scholar
• de Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. European Society of Cardiology.13.03.2020
   Google Scholar
• Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. American College of Cardiology. 17.03.2020
   Google Scholar
• U.S. National Library of Medicine. 2020 Available from: ClinicalTrials.Gov. ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 67, 2020.
   Google Scholar
• University Hospital Strasbourg France. Efficacy of hydroxychloroquine, telmisartan and azithromycin on the survival of hospitalized elderly patients with COVID-19 (COVID-aging). 2020 Available from: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT4359953?term=arb&cond=covid-19&draw=5&rank=36. Accessed 67, 2020.
   Google Scholar